Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that is revolutionizing the effective delivery and potentiation of oncolytic viruses for targeted therapy against difficult-to-treat cancers. Calidi Biotherapeutics is advancing in clinical development a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/23/23 | $25,000,000 | Series B |
Calidi Cure Jackson Investment Group  | undisclosed |
